Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tusamitamab ravtansine - Sanofi

Drug Profile

Tusamitamab ravtansine - Sanofi

Alternative Names: IBI-126; Maytansin-loaded anti-CEACAM5 mAb; SAR '701; SAR-408701

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer Erasmus MC; Sanofi
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Feb 2024 Sanofi withdrew a phase II trial in Breast cancer, Non small cell lung cancer and Gastric cancer (Metastatic disease, Second-line therapy or greater) in Netherlands (IV) prior to enrollment due to the decision to discontinue the candidate's global clinical development (EudraCT2022-003451-34; NCT05703555)
  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 21 Dec 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top